The FDA has approved Aciphex (rabeprazole sodium, from Eisai) for the short-term treatment of gastroesophageal reflux disease (GERD) in adolescents ≥12 years of age. In a 12-week study, Aciphex was shown to be well tolerated in adolescents and had a safety profile similar to that of adults.

Aciphex is already indicated for use in adults for the short-term treatment and symptom relief of damaging GERD or treatment of duodenal ulcers, the maintenance of GERD healing, and long-term treatment of pathological hypersecretory conditions such as Zollinger-Ellison syndrome.

For more information call (888) 4-ACIPHEX or visit www.aciphex.com.